| Troy Sibbett, CRNA | |
|
835 Se Bishop Blvd, Pullman, WA 99163-5512 | |
| (509) 332-2541 | |
| Not Available |
| Full Name | Troy Sibbett |
|---|---|
| Gender | Male |
| Speciality | Certified Registered Nurse Anesthetist (crna) |
| Experience | 3 Years |
| Location | 835 Se Bishop Blvd, Pullman, Washington |
| Accepts Medicare Assignments | Yes. He accepts the Medicare-approved amount; you will not be billed for any more than the Medicare deductible and coinsurance. |
| Identifier | Type | State | Issuer |
|---|---|---|---|
| 1881276343 | NPI | - | NPPES |
| Taxonomy | Type | License (State) | Status |
|---|---|---|---|
| 367500000X | Nurse Anesthetist, Certified Registered | 134945 (Nebraska) | Primary |
| Facility Name | Location | Facility Type |
|---|---|---|
| Pullman Regional Hospital | Pullman, WA | Hospital |
| Group Practice Name | Group PECOS PAC ID | No. of Members |
|---|---|---|
| Public Hospital District 1-a Of Whitman County | 8325934987 | 50 |
News Archive
Sorrento Therapeutics, Inc. ("Sorrento" or the "Company"), a late-stage clinical oncology company developing new treatments for cancer and its associated pain, today announced the pricing of an underwritten public offering of 4,765,000 shares of common stock at a public offering price of $5.25 per share.
In this post in the Department of State's "DipNote" blog, U.S. Global AIDS Coordinator Ambassador Eric Goosby reflects on his speech at the Brookings Institution on Tuesday in anticipation of the AIDS 2012 conference scheduled to take place in Washington, D.C. from July 22-27.
In the current BioPharma economic climate; with smaller companies desperately needing the right development partners for survival and larger ones needing to support their existing businesses through making the right deals, having the best, most comprehensive, intelligence and insights are absolutely essential for success.
Researchers from Boston University School of Medicine have shown that use of magnetic resonance imaging in an animal model can non-invasively identify dangerous plaques. The findings, which appear in the May issue of Circulation Cardiovascular Imaging, offer possible applications in the diagnosis and treatment of patients with atherosclerosis.
› Verified 6 days ago
| Entity Name | Public Hospital District #1-a Of Whitman County |
|---|---|
| Entity Type | Part B Supplier - Clinic/group Practice |
| Entity Identifiers | NPI Number: 1366446767 PECOS PAC ID: 8325934987 Enrollment ID: O20040223000506 |
News Archive
Sorrento Therapeutics, Inc. ("Sorrento" or the "Company"), a late-stage clinical oncology company developing new treatments for cancer and its associated pain, today announced the pricing of an underwritten public offering of 4,765,000 shares of common stock at a public offering price of $5.25 per share.
In this post in the Department of State's "DipNote" blog, U.S. Global AIDS Coordinator Ambassador Eric Goosby reflects on his speech at the Brookings Institution on Tuesday in anticipation of the AIDS 2012 conference scheduled to take place in Washington, D.C. from July 22-27.
In the current BioPharma economic climate; with smaller companies desperately needing the right development partners for survival and larger ones needing to support their existing businesses through making the right deals, having the best, most comprehensive, intelligence and insights are absolutely essential for success.
Researchers from Boston University School of Medicine have shown that use of magnetic resonance imaging in an animal model can non-invasively identify dangerous plaques. The findings, which appear in the May issue of Circulation Cardiovascular Imaging, offer possible applications in the diagnosis and treatment of patients with atherosclerosis.
› Verified 6 days ago
| Entity Name | Pullman Anesthesia Pllc |
|---|---|
| Entity Type | Part B Supplier - Clinic/group Practice |
| Entity Identifiers | NPI Number: 1023676004 PECOS PAC ID: 8325374150 Enrollment ID: O20190731001913 |
News Archive
Sorrento Therapeutics, Inc. ("Sorrento" or the "Company"), a late-stage clinical oncology company developing new treatments for cancer and its associated pain, today announced the pricing of an underwritten public offering of 4,765,000 shares of common stock at a public offering price of $5.25 per share.
In this post in the Department of State's "DipNote" blog, U.S. Global AIDS Coordinator Ambassador Eric Goosby reflects on his speech at the Brookings Institution on Tuesday in anticipation of the AIDS 2012 conference scheduled to take place in Washington, D.C. from July 22-27.
In the current BioPharma economic climate; with smaller companies desperately needing the right development partners for survival and larger ones needing to support their existing businesses through making the right deals, having the best, most comprehensive, intelligence and insights are absolutely essential for success.
Researchers from Boston University School of Medicine have shown that use of magnetic resonance imaging in an animal model can non-invasively identify dangerous plaques. The findings, which appear in the May issue of Circulation Cardiovascular Imaging, offer possible applications in the diagnosis and treatment of patients with atherosclerosis.
› Verified 6 days ago
| Mailing Address | Practice Location Address |
|---|---|
| Troy Sibbett, CRNA 4624 N Fieldcrest Way, Boise, ID 83704-1249 Ph: (208) 585-7174 | Troy Sibbett, CRNA 835 Se Bishop Blvd, Pullman, WA 99163-5512 Ph: (509) 332-2541 |
News Archive
Sorrento Therapeutics, Inc. ("Sorrento" or the "Company"), a late-stage clinical oncology company developing new treatments for cancer and its associated pain, today announced the pricing of an underwritten public offering of 4,765,000 shares of common stock at a public offering price of $5.25 per share.
In this post in the Department of State's "DipNote" blog, U.S. Global AIDS Coordinator Ambassador Eric Goosby reflects on his speech at the Brookings Institution on Tuesday in anticipation of the AIDS 2012 conference scheduled to take place in Washington, D.C. from July 22-27.
In the current BioPharma economic climate; with smaller companies desperately needing the right development partners for survival and larger ones needing to support their existing businesses through making the right deals, having the best, most comprehensive, intelligence and insights are absolutely essential for success.
Researchers from Boston University School of Medicine have shown that use of magnetic resonance imaging in an animal model can non-invasively identify dangerous plaques. The findings, which appear in the May issue of Circulation Cardiovascular Imaging, offer possible applications in the diagnosis and treatment of patients with atherosclerosis.
› Verified 6 days ago
Mr. John Anthony Schirmer, CRNA, NSPM-C Nurse Anesthetist - CR Medicare: Accepting Medicare Assignments Practice Location: 835 Se Bishop Blvd, Pullman, WA 99163 Phone: 509-336-7569 | |
Kyle James Jennings, CRNA-ARNP Nurse Anesthetist - CR Medicare: Accepting Medicare Assignments Practice Location: 835 Se Bishop Blvd, Pullman, WA 99163 Phone: 018-633-4564 | |
Corey Dean Johnson, CRNA Nurse Anesthetist - CR Medicare: Accepting Medicare Assignments Practice Location: 835 Se Bishop Blvd, Pullman, WA 99163 Phone: 509-332-4051 Fax: 509-332-4051 | |
Wesley M Wolcott, CRNA Nurse Anesthetist - CR Medicare: Accepting Medicare Assignments Practice Location: 835 Se Bishop Blvd, Pullman, WA 99163 Phone: 509-332-2541 | |
Edward R Winterbottom, CRNA Nurse Anesthetist - CR Medicare: Medicare Enrolled Practice Location: 835 Se Bishop Blvd, Pullman, WA 99163 Phone: 509-332-2541 | |
Karl G Spens, CRNA Nurse Anesthetist - CR Medicare: Accepting Medicare Assignments Practice Location: 820 Sw Center St, Pullman, WA 99163 Phone: 706-717-0563 |